← Leaderboards
Kornelia Polyak
Dana-Farber Cancer Inst
$28,582,691
Attributed
$31,701,905
Total exposure
18
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$49,797,368 · 20
By mechanism
P50$14,063,464 · 8
P01$13,090,015 · 5
R35$11,353,199 · 1
U01$5,848,818 · 2
R01$3,394,227 · 2
U54$1,957,469 · 1
Top collaborators
- Joe W. Gray5 shared
- Franziska Michor5 shared
- Paul T Spellman5 shared
- Nancy U Lin4 shared
- Geoffrey I Shapiro4 shared
- Mina J Bissell2 shared
- Jeffrey W. Pollard2 shared
- Leif W Ellisen1 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Michael J Eck$25,871,961
- Tracy T Batchelor$27,819,477
- Shuqiang Li$1,050,856
- David A Barbie$12,794,638
- Nathanael Schiander Gray$36,761,550
Others in their field
Top investigators on “Malignant Breast Neoplasm”
- David Heimbrook · Leidos Biomedical Research, Inc.$347,312,063
- Norman Wolmark · Nsabp Foundation, Inc.$122,067,540
- Walter John Curran · Thomas Jefferson University$97,002,422
- Monica M Bertagnolli · Strang Cancer Prevention Center$84,975,759
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$68,847,428
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$60,763,376
Research focus
Malignant Breast NeoplasmMammary NeoplasmsTumorBaseCellsResistanceTherapy ResistantMolecularClinical TrialsCell TypeHeterogeneityCombined Modality TherapyPhenotypeDesignMalignant NeoplasmsEpigenetic ProcessProgramsSamplingXenograft ProcedureTargeted TreatmentTriple-Negative Invasive Breast CarcinomaTreatment StrategyCancer TherapyMolecular Profiling
Grant awards (90)
Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer$2,607,297
P50 · FY2025 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$1,060,812
R35 · FY2025 · CA · contact PI
Project 3: BET bromodomain inhibitor combinations in breast cancer$266,003
P50 · FY2025 · CA · contact PI
Administration, Advocacy, Planning and Communication Core$199,906
P50 · FY2025 · CA · contact PI
Program 15: Cancer Cell Biology$50,490
P30 · FY2025 · CA · contact PI
New therapeutic vulnerabilities in breast cancer$1,666,032
P01 · FY2024 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$1,007,771
R35 · FY2024 · CA · contact PI
Epigenetic mechanisms of therapeutic resistance$358,746
P01 · FY2024 · CA · contact PI
Administrative Core - New therapeutic vulnerabilities in breast cancer$113,686
P01 · FY2024 · CA · contact PI
Program 15: Cancer Cell Biology$39,686
P30 · FY2024 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer$2,302,230
P50 · FY2023 · CA · contact PI
New therapeutic vulnerabilities in breast cancer$1,718,646
P01 · FY2023 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$1,015,451
R35 · FY2023 · CA · contact PI
Epigenetic mechanisms of therapeutic resistance$358,778
P01 · FY2023 · CA · contact PI
Project 4: Combined use of immunotherapy and targeted treatments for triple negative breast cancer$301,775
P50 · FY2023 · CA · contact PI
Core A: Administrative$201,464
P50 · FY2023 · CA · contact PI
Administrative Core - New therapeutic vulnerabilities in breast cancer$113,434
P01 · FY2023 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer$2,210,645
P50 · FY2022 · CA · contact PI
New therapeutic vulnerabilities in breast cancer$1,718,646
P01 · FY2022 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$1,060,812
R35 · FY2022 · CA · contact PI
Epigenetic mechanisms of therapeutic resistance$358,778
P01 · FY2022 · CA · contact PI
Project 4: Combined use of immunotherapy and targeted treatments for triple negative breast cancer$290,647
P50 · FY2022 · CA · contact PI
Administrative Core - New therapeutic vulnerabilities in breast cancer$113,434
P01 · FY2022 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer$2,345,277
P50 · FY2021 · CA · contact PI
New therapeutic vulnerabilities in breast cancer$1,753,720
P01 · FY2021 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$1,157,073
R35 · FY2021 · CA · contact PI
Epigenetic mechanisms of therapeutic resistance$366,098
P01 · FY2021 · CA · contact PI
Project 4: Combined use of immunotherapy and targeted treatments for triple negative breast cancer$330,532
P50 · FY2021 · CA · contact PI
Administrative Core - New therapeutic vulnerabilities in breast cancer$115,750
P01 · FY2021 · CA · contact PI
New therapeutic vulnerabilities in breast cancer$1,772,970
P01 · FY2020 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$1,157,072
R35 · FY2020 · CA · contact PI
Epigenetic mechanisms of therapeutic resistance$366,097
P01 · FY2020 · CA · contact PI
Project 4: Combined use of immunotherapy and targeted treatments for triple negative breast cancer$316,411
P50 · FY2020 · CA · contact PI
Project 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer Therapy$126,492
U54 · FY2020 · CA · contact PI
Administrative Core - New therapeutic vulnerabilities in breast cancer$124,875
P01 · FY2020 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$1,122,360
R35 · FY2019 · CA · contact PI
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors$645,619
U01 · FY2019 · CA · contact PI
Project 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer Therapy$338,577
U54 · FY2019 · CA · contact PI
Project 4: Combined use of immunotherapy and targeted treatments for triple negative breast cancer$275,841
P50 · FY2019 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$1,157,073
R35 · FY2018 · CA · contact PI
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors$671,607
U01 · FY2018 · CA · contact PI
Project 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer Therapy$268,348
U54 · FY2018 · CA · contact PI
The Role of P27 in Breast Epithelial Progenitors and Breast Cancer Risk$192,594
P01 · FY2018 · CA · contact PI
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors$666,735
U01 · FY2017 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$546,708
R35 · FY2017 · CA · contact PI
Project 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer Therapy$414,812
U54 · FY2017 · CA · contact PI
BET Bromodomain proteins as Novel Therapeutic Targets in Triple Negative Breast Cancer$231,345
P50 · FY2017 · CA · contact PI
The Role of P27 in Breast Epithelial Progenitors and Breast Cancer Risk$191,597
P01 · FY2017 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$1,035,000
R35 · FY2016 · CA · contact PI
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors$672,917
U01 · FY2016 · CA · contact PI
Project 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer Therapy$416,678
U54 · FY2016 · CA · contact PI
BET Bromodomain proteins as Novel Therapeutic Targets in Triple Negative Breast Cancer$246,702
P50 · FY2016 · CA · contact PI
The Role of P27 in Breast Epithelial Progenitors and Breast Cancer Risk$190,367
P01 · FY2016 · CA · contact PI
Targeting intratumor heterogeneity in breast cancer$1,033,067
R35 · FY2015 · CA · contact PI
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors$682,376
U01 · FY2015 · CA · contact PI
Project 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer Therapy$392,562
U54 · FY2015 · CA · contact PI
BET Bromodomain proteins as Novel Therapeutic Targets in Triple Negative Breast$248,628
P50 · FY2015 · CA · contact PI
The Role of P27 in Breast Epithelial Progenitors and Breast Cancer Risk$197,084
P01 · FY2015 · CA · contact PI
BET Bromodomain proteins as Novel Therapeutic Targets in Triple Negative Breast$251,589
P50 · FY2014 · CA · contact PI
The Role of P27 in Breast Epithelial Progenitors and Breast Cancer Risk$201,329
P01 · FY2014 · CA · contact PI
Myoepithelial cell differentiation defects in ductal carcinoma in situ (DCIS)$417,380
U01 · FY2013 · CA · contact PI
BET Bromodomain proteins as Novel Therapeutic Targets in Triple Negative Breast$243,677
P50 · FY2013 · CA · contact PI
Role of Chromatin in Defining Breast Epithelial Cell Phenotypes$200,219
P01 · FY2013 · CA · contact PI
Myoepithelial cell differentiation defects in ductal carcinoma in situ (DCIS)$504,780
U01 · FY2012 · CA · contact PI
Role of Chromatin in Defining Breast Epithelial Cell Phenotypes$217,557
P01 · FY2012 · CA · contact PI
Myoepithelial cell differentiation defects in ductal carcinoma in situ (DCIS)$477,465
U01 · FY2011 · CA · contact PI
Role of Chromatin in Defining Breast Epithelial Cell Phenotypes$217,274
P01 · FY2011 · CA · contact PI
Myoepithelial cell differentiation defects in ductal carcinoma in situ (DCIS)$534,748
U01 · FY2010 · CA · contact PI
Epithelial-stromal cell interactions in breast cancer$294,724
R01 · FY2010 · CA · contact PI
Role of Chromatin in Defining Breast Epithelial Cell Phenotypes$228,987
P01 · FY2010 · CA · contact PI
Myoepithelial cell differentiation defects in ductal carcinoma in situ (DCIS)$575,191
U01 · FY2009 · CA · contact PI
The Role of Stromal Cells and Stromal-Epithelial Interaction in the Early Stages$312,607
P50 · FY2009 · CA · contact PI
Epithelial-stromal cell interactions in breast cancer$294,724
R01 · FY2009 · CA · contact PI
Epithelial-stromal cell interactions in breast cancer$287,071
R01 · FY2009 · CA · contact PI
Role of Chromatin in Defining Breast Epithelial Cell Phenotypes$233,317
P01 · FY2009 · CA · contact PI
Epithelial-stromal cell interactions in breast cancer$294,724
R01 · FY2008 · CA · contact PI
The Role of Stromal Cells and Stromal-Epithelial Interaction in the Early Stages$183,111
P50 · FY2008 · CA · contact PI
P-5: Stromal-Epithelial Interactions and Implications for Risk Prevention & Treat$301,914
P50 · FY2007 · CA · contact PI
Epithelial-stromal cell interactions in breast cancer$294,724
R01 · FY2007 · CA · contact PI
HIN-1,A Novel Putative Breast Tumor Suppressor Gene$318,954
R01 · FY2006 · CA · contact PI
Epithelial-stromal cell interactions in breast cancer$302,638
R01 · FY2006 · CA · contact PI
P-5: Stromal-Epithelial Interactions and Implications for Risk Prevention & Treat$198,006
P50 · FY2006 · CA · contact PI
HIN-1,A Novel Putative Breast Tumor Suppressor Gene$326,630
R01 · FY2005 · CA
P-5: Stromal-Epithelial Interactions and Implications for Risk Prevention &Treat$197,857
P50 · FY2005 · CA
HIN-1,A Novel Putative Breast Tumor Suppressor Gene$326,630
R01 · FY2004 · CA
HIN-1,A Novel Putative Breast Tumor Suppressor Gene$326,630
R01 · FY2003 · CA
HIN-1,A Novel Putative Breast Tumor Suppressor Gene$326,778
R01 · FY2002 · CA
Molecular markers in DCIS$0
P50 · FY2002 · CA
Molecular markers in DCIS$0
P50 · FY2001 · CA
Molecular markers in DCIS$0
P50 · FY2000 · CA